Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
1.930
-0.060 (-3.02%)
At close: Aug 14, 2026, 4:00 PM EDT
2.060
+0.130 (6.74%)
After-hours: Aug 14, 2026, 7:55 PM EDT
Alaunos Therapeutics Revenue
Alaunos Therapeutics had revenue of $3.00K in the twelve months ending March 31, 2026, down -70.00% year-over-year. In the year 2025, Alaunos Therapeutics had annual revenue of $5.00K, down -50.00%.
Revenue (ttm)
$3.00K
Revenue Growth
-70.00%
P/S Ratio
1,558.25
Revenue / Employee
$3,000
Employees
1
Market Cap
4.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00K | -5.00K | -50.00% |
| Dec 31, 2024 | 10.00K | 5.00K | 100.00% |
| Dec 31, 2023 | 5.00K | -2.92M | -99.83% |
| Dec 31, 2022 | 2.92M | 2.52M | 634.17% |
| Dec 31, 2021 | 398.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 146.00K | -6.24M | -97.71% |
| Dec 31, 2017 | 6.39M | -472.00K | -6.88% |
| Dec 31, 2016 | 6.86M | 2.53M | 58.38% |
| Dec 31, 2015 | 4.33M | 2.96M | 215.51% |
| Dec 31, 2014 | 1.37M | 573.00K | 71.63% |
| Dec 31, 2013 | 800.00K | - | - |
| Dec 31, 2012 | 800.00K | 133.00K | 19.94% |
| Dec 31, 2011 | 667.00K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.50M |
| BioAtla | 2.00M |
| PMGC Holdings | 1.27M |
| GeoVax Labs | 852.28K |
| BioRestorative Therapies | 357.87K |
| Silo Pharma | 72.10K |
| Pulmatrix | 3.00K |
TCRT News
- 2 months ago - Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies - TheFly
- 2 months ago - Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies - GlobeNewsWire
- 3 months ago - Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies - TheFly
- 3 months ago - Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - GlobeNewsWire
- 3 months ago - Alaunos Therapeutics Quarterly report: Q1 2026 - Filings
- 3 months ago - Valion Bio Appoints Melinda Lackey as General Counsel - PRNewsWire
- 4 months ago - Alaunos Therapeutics Annual report: Q4 2025 - Filings
- 5 months ago - Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003 - TheFly